Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.
EHC 2023
Programm
Personen
Suche
EN
Zurück
Poster session
PoS 1
ePoster 04
Termin
Datum:
06.12.2023
Zeit:
19:30
–
21:00
Ort / Stream:
ePoster station 4
Chair
Alicia Gonzalez-Martinez
Madrid, ES
Programm
ePoster
P055
Galcanezumab for migraine prevention in patients above 65: a multicenter study in real-world settings
Julia Peris-Subiza (Barcelona, ES)
ePoster
P058
Evaluation of the accuracy of the predictive algorithm of response to anti-CGRP monoclonal antibodies in patients with migraine older than 65 years: external validation study
Alicia Gonzalez-Martinez (Madrid, ES)
ePoster
P060
Effectiveness and tolerability of CGRP monoclonal antibodies in combination with monoclonal antibodies for other diseases: a multicenter study
Francesca Pistoia (L'Aquila, IT)
ePoster
P061
Evaluation of the concomitant use of preventive treatments in patients with migraine under anti-CGRP therapies: the PREVENAC study
Alicia Gonzalez-Martinez (Madrid, ES)
ePoster
P062
Headache due to excessive use of medication: prevalence after preventive treatment with antibodies directed against the CGRP pathway
Paula Santamaría Montero (Lugo, ES)
Laura Abraira Carballido (Lugo, ES)
ePoster
P063
Question: Can monoclonal antibodies prevent chronic migraine without aura?
George Chakhava (Tbilisi, GE)
ePoster
P064
Botulinum toxin as an off-label treatment of other primary and secondary headaches
Beatriz Nunes Vicente (Lisbon, PT)
ePoster
P065
Adverse effects of CGRP mAbs: experience from a tertiary center in migraine treatment
Catarina Fernandes (Coimbra, PT)
ePoster
P066
Real world experience after one year of treatment with antiCGRP monoclonal antibodies in patients with chronic migraine
Vicente González-Quintanilla (Santander, ES)
Jorge Madera Fernandez (Santander, ES)
Gabriel Gárate (Santander, ES)
ePoster
P069
Amitriptyline versus quetiapine for migraine prophylaxis in Saudi population
Anas Alasmari (Jeddah, SA)
ePoster
P070
Preventive and therapeutic effects of rimegepant on medication overuse headache: based on a mouse model that is more in line with clinical characteristics
Zhenjie Ma (Beijing, CN)
Chenhao Li (Beijing, CN)
ePoster
P071
Ubrogepant in the treatment of vestibular migraine: case report
Bradley Torphy (Chicago, US)
© Conventus Congressmanagement & Marketing GmbH
Impressum
Datenschutz